Condition: High Grade Glioma · Astrocytoma · Astrocytoma, Grade III · Sponsor: Rigel Pharmaceuticals
The goal of this study is to determine the efficacy of the study drug olutasidenib to treat newly diagnosed pediatric and young adult patients with a high-grade glioma (HGG) harboring an IDH1 mutation. The main question the study aims to answer is whether the combination of olutasidenib and temozolomide (TMZ) can prolong the life of patients diagnosed with an IDH-mutant HGG.
This description comes directly from the study's public registry record.
Jill DeFratis, MPH · 650-624-1100 · jdefratis@rigel.com
Vanessa Tan · 650-624-1100 · clinicaltrials@rigel.com
Always discuss trial participation with your own doctor first.
| Children's Hospital Colorado | Aurora, Colorado, United States | Not Yet Recruiting |
| Children's National Medical Center | Washington D.C., District of Columbia, United States | Not Yet Recruiting |
| University of Miami Hospital and Clinics | Miami, Florida, United States | Recruiting |
| Ann & Robert H. Lurie Children's Hospital of Chicago | Chicago, Illinois, United States | Recruiting |
| Susan Chi | Boston, Massachusetts, United States | Not Yet Recruiting |
| Duke University Health System | Durham, North Carolina, United States | Recruiting |
| Cincinnati Children's Hospital Medical Center | Cincinnati, Ohio, United States | Recruiting |
| Nationwide Children's Hospital | Columbus, Ohio, United States | Recruiting |
| Children's Hospital of Philadelphia | Philadelphia, Pennsylvania, United States | Not Yet Recruiting |
| Texas Children's Hospital | Houston, Texas, United States | Not Yet Recruiting |
| Seattle Children's Hospital | Seattle, Washington, United States | Recruiting |
| Sydney Children's Hospital | Randwick, New South Wales, Australia | Recruiting |
+ 8 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06161974